Sparc

SPARC shares crash 19% after Psoriasis drug fails to deliver in trials

SPARC tumbled 19 percent after Phase 2 trials of its psoriasis drug SCD-044 failed to meet primary endpoints. The company will halt further development and assess next steps

SPARC up 12% ahead of update on clinical programs, R&D pipeline this week

SPARC has a market capitalisation close to Rs 7,600 crore and the shares are down by 23% so far this year. On charts, the share has given a strong breakout rising above the 10 and 20 EMA.

Sun Pharma Advanced slips 5% on halting Parkinson's drug trial

The Sun Pharma Advanced Research Company stock has gained 40 percent this year against a 4 percent rise in the benchmark Nifty50

Sun Pharma inks licensing pact with SPARC to commercialise medication in US market

The Mumbai-based drug maker has inked a pact with Sun Pharma Advanced Research Company (SPARC) to commercialise benzyl alcohol and propylene glycol-free phenobarbital sodium powder for injection in the US.

Trade Spotlight | What should you do with Shoppers Stop, Sharda Cropchem, SPARC, Hitachi Energy and Bajaj Auto?

Trade Spotlight | Here's what Rajesh Palviya of Axis Securities recommends investors should do with these stocks when the market resumes trading today

SPARC inks licensing pact with Visiox Pharma for ophthalmic products

The company has entered into an agreement with Visiox Pharma LLC (Visiox) to grant exclusive worldwide rights (except for India and Greater China) for the development and commercialisation of PDP-716 and SDN-037, SPARC said in a statement.

Dilip Shanghvi resigns as MD of SPARC: Here's what you need to know about him

Dilip Shanghvi will continue to be SPARC's chairman and a non-executive director on the board.

Union Education Ministry releases Rs 80 crore to IIT Kharagpur for second phase of SPARC

Adrijit Goswami from IIT Kharagpur, who is heading the Pan India coordination of the programme, said the allocation would help in promoting virtual and e-learning.

'Nifty to head towards 12,700 levels, but money will likely be made in mid & smallcaps'

Our advice would be to accumulate longs in the Nifty with the stop loss of 12100 levels, and any close above 12400 could push Nifty towards the targets of 12735.

Abraxis Bioscience LLC dismisses patent infringement complaint against SPARC

"Abraxis Biosciences LLC has dismissed the patent infringement complaint filed against Sun Pharma Advanced Research Co Ltd regarding SPARC's New Drug Application for PICS (Paclitaxel Injection Concentrate for Suspension)," the company said in a regulatory fling.

Market Headstart: Nifty50 seen opening higher; 3 stocks which could give 5-10% return

Trends on SGX Nifty indicate a higher opening for the broader index in India, a gain of 41 points or 0.35 percent. Nifty futures were trading around 11,643-level on the Singaporean Exchange.

Market Headstart | Nifty likely to open flat; 3 stocks that could give 7-12% return

A positive opening is likely as Nifty Futures on Singaporean Exchange were trading 21.5 points higher. The futures traded around 10,897-odd levels.

Podcast | Stock picks of the day: Nifty could remain in upward consolidation mode

On the higher end, the Nifty may move towards 11,000. On the other hand, support is pegged at 10,700

SPARC, Schrödinger announce research collaboration for novel CNS therapeutics

This collaboration will leverage Schrödinger's advanced computational platform and SPARC's extensive drug development expertise and insights in neuro-degeneration, the companies said in a joint statement.

SPARC jumps 8% on successful pivotal bioequivalence study for cancer drug

PICS is a novel formulation of Paclitaxel developed using SPARC's proprietary Nanotecton technology.

Market Now: Jewellery stocks shine - PC Jeweller, Titan up 3-4%; ICICI Bank top gainer

Jewellery stocks, the likes of PC Jeweller and Titan Company which were up between 3-4 percent while ICICI Bank was the top gainer in the Nifty50 Index while SPARC plunged 11 percent intraday.

SPARC jumps 4% on topline results of PIF and low dose PK study for dry powder inhaler

Anil Raghavan, CEO, SPARC, the results confirms that device is highly efficient and consistent in delivering more drug to the lungs and suitable for all classes of patients.

Stocks in the news: Bajaj Auto, Laurus Labs, M&M, Bhushan Steel, SPARC, Deccan Cements

SPARC spikes 7% on USFDA's complete response letter for Xelpros

Shares of Sun Pharma Advanced Research Company, the subsidiary of healthcare major Sun Pharmaceutical, surged nearly 7 percent intraday Thursday after receiving complete response letter from the US health regulator for preservative-free eye drop.

Sensex, Nifty continue to fall; Midcap breaks 200-DMA, SPARC up

The selling pressure continued for the seventh consecutive session today due to lack of positive triggers. The market may be factoring in the impact of demonetisation on December quarter earnings, December sales data and economic data that will be announced next month.